Validation of a methylation-based signature for subventricular zone involvement in glioblastoma.

Glioblastoma IDH Methylation Overall survival Subventricular zone Wild type

Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
20 Feb 2024
Historique:
received: 12 12 2023
accepted: 11 01 2024
medline: 20 2 2024
pubmed: 20 2 2024
entrez: 20 2 2024
Statut: aheadofprint

Résumé

Glioblastomas (GBM) with subventricular zone (SVZ) contact have previously been associated with a specific epigenetic fingerprint. We aim to validate a reported bulk methylation signature to determine SVZ contact. Methylation array analysis was performed on IDHwt GBM patients treated at our institution. The v11b4 classifier was used to ensure the inclusion of only receptor tyrosine kinase (RTK) I, II, and mesenchymal (MES) subtypes. Methylation-based assignment (SVZM ±) was performed using hierarchical cluster analysis. Magnetic resonance imaging (MRI) (T1ce) was independently reviewed for SVZ contact by three experienced readers. Sixty-five of 70 samples were classified as RTK I, II, and MES. Full T1ce MRI-based rater consensus was observed in 54 cases, which were retained for further analysis. Epigenetic SVZM classification and SVZ were strongly associated (OR: 15.0, p = 0.003). Thirteen of fourteen differential CpGs were located in the previously described differentially methylated LRBA/MAB21L2 locus. SVZ + tumors were linked to shorter OS (hazard ratio (HR): 3.80, p = 0.02) than SVZM + at earlier time points (time-dependency of SVZM, p < 0.05). Considering the SVZ consensus as the ground truth, SVZM classification yields a sensitivity of 96.6%, specificity of 36.0%, positive predictive value (PPV) of 63.6%, and negative predictive value (NPV) of 90.0%. Herein, we validated the specific epigenetic signature in GBM in the vicinity of the SVZ and highlighted the importance of methylation of a part of the LRBA/MAB21L2 gene locus. Whether SVZM can replace MRI-based SVZ assignment as a prognostic and diagnostic tool will require prospective studies of large, homogeneous cohorts.

Identifiants

pubmed: 38376766
doi: 10.1007/s11060-024-04570-0
pii: 10.1007/s11060-024-04570-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Ostrom QT et al (2022) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro-Oncology 24(Supplement_5):v1–v95
doi: 10.1093/neuonc/noac202 pubmed: 36196752 pmcid: 9533228
Weller M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170–186
doi: 10.1038/s41571-020-00447-z pubmed: 33293629
Lathia JD et al (2015) Cancer stem cells in glioblastoma. Genes Dev 29(12):1203–1217
doi: 10.1101/gad.261982.115 pubmed: 26109046 pmcid: 4495393
Lim DA, Alvarez-Buylla A (2016) The adult ventricular-subventricular zone (V-SVZ) and olfactory bulb (OB) neurogenesis. Cold Spring Harb Perspect Biol 8(5):a018820
Altmann C, Keller S, Schmidt MHH (2019) The role of SVZ stem cells in glioblastoma. Cancers 11(4):448
doi: 10.3390/cancers11040448 pubmed: 30934929 pmcid: 6521108
Lee JH et al (2018) Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 560(7717):243–247
doi: 10.1038/s41586-018-0389-3 pubmed: 30069053
Bartkowiak T et al (2023) An immunosuppressed microenvironment distinguishes lateral ventricle-contacting glioblastomas. JCI Insight 8(12):e160652
Sanai N, Alvarez-Buylla A, Berger MS (2005) Neural stem cells and the origin of gliomas. N Engl J Med 353(8):811–822
doi: 10.1056/NEJMra043666 pubmed: 16120861
Louis DN et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251
doi: 10.1093/neuonc/noab106 pubmed: 34185076 pmcid: 8328013
Capper D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555(7697):469–474
doi: 10.1038/nature26000 pubmed: 29539639 pmcid: 6093218
Hira VVV et al (2021) Immunohistochemical detection of neural stem cells and glioblastoma stem cells in the subventricular zone of glioblastoma patients. J Histochem Cytochem 69(5):349–364
doi: 10.1369/0022155421994679 pubmed: 33596115 pmcid: 8091546
Adeberg S et al (2022) DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma. Acta Neuropathol 144(1):129–142
doi: 10.1007/s00401-022-02443-2 pubmed: 35660939 pmcid: 9217840
Mistry AM (2019) Clinical correlates of subventricular zone-contacting glioblastomas: a meta-analysis. J Neurosurg Sci 63(5):581–587
doi: 10.23736/S0390-5616.17.04274-6 pubmed: 29205011
Aryee MJ et al (2014) Minfi: a flexible and comprehensive bioconductor package for the analysis of infinium DNA methylation microarrays. Bioinformatics 30(10):1363–1369
doi: 10.1093/bioinformatics/btu049 pubmed: 24478339 pmcid: 4016708
Knoll M (2020) DataAnalysisMisc: collection of functions for daily tasks. In: R package version 0.99.11
Therneau T, Grambsch P (2000) Modeling survival data: extending the cox model. Springer, New York
doi: 10.1007/978-1-4757-3294-8
Kerkhof M et al (2016) Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme. Eur J Neurol 23(10):1528–1533
doi: 10.1111/ene.13070 pubmed: 27424939
Thust SC et al (2018) Glioma imaging in Europe: a survey of 220 centres and recommendations for best clinical practice. Eur Radiol 28(8):3306–3317
doi: 10.1007/s00330-018-5314-5 pubmed: 29536240 pmcid: 6028837
Nourallah B et al (2017) Irradiating the subventricular zone in glioblastoma patients: is there a case for a clinical trial? Clin Oncol (R Coll Radiol) 29(1):26–33
doi: 10.1016/j.clon.2016.09.005 pubmed: 27729188
Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S (2013) Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol 15(1):91–6
doi: 10.1093/neuonc/nos268 pubmed: 23095230
Zhao K et al (2022) The imaging features and prognosis of gliomas involving the subventricular zone: an MRI study. Clin Neurol Neurosurg 222:107465
doi: 10.1016/j.clineuro.2022.107465 pubmed: 36201899
Barami K et al (2009) Relationship of gliomas to the ventricular walls. J Clin Neurosci 16(2):195–201
doi: 10.1016/j.jocn.2008.03.006 pubmed: 19097905
Mistry AM et al (2019) Ventricular-subventricular zone contact by glioblastoma is not associated with molecular signatures in bulk tumor data. Sci Rep 9(1):1842
doi: 10.1038/s41598-018-37734-w pubmed: 30755636 pmcid: 6372607
Lin CA et al (2017) Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma. Cell Cycle 16(8):765–775
doi: 10.1080/15384101.2017.1295186 pubmed: 28278055 pmcid: 5405724
Carrano A et al (2021) Human cerebrospinal fluid modulates pathways promoting glioblastoma malignancy. Front Oncol 11:624145
Lim DA et al (2007) Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol 9(4):424–429
doi: 10.1215/15228517-2007-023 pubmed: 17622647 pmcid: 1994099
Ahmadipour Y et al (2020) The influence of subventricular zone involvement in extent of resection and tumor growth pattern of glioblastoma. Innov Surg Sci 5(3–4):127–132
pubmed: 34966832 pmcid: 8668024
Hallaert G et al (2020) Subventricular zone contacting glioblastoma: tumor size, molecular biological factors and patient survival. Acta Oncol 59(12):1474–1479
doi: 10.1080/0284186X.2020.1794032 pubmed: 32672481
Bender K et al (2021) What is the role of the subventricular zone in radiotherapy of glioblastoma patients? Radiother Oncol 158:138–145
doi: 10.1016/j.radonc.2021.02.017 pubmed: 33636228

Auteurs

Felix Ehret (F)

Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany. felix.ehret@charite.de.
Charité - Universitätsmedizin Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany. felix.ehret@charite.de.

Oliver Zühlke (O)

Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.

Leonille Schweizer (L)

Institute of Neurology (Edinger Institute), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Johannes Kahn (J)

Department of Radiology, Health and Medical University, Potsdam, Germany.

Christoph Csapo-Schmidt (C)

Department of Neuroradiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.

Siyer Roohani (S)

Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Junior Clinician Scientist Program, Berlin, Germany.

Daniel Zips (D)

Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.

David Capper (D)

Charité - Universitätsmedizin Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Neuropathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.

Sebastian Adeberg (S)

Department of Radiation Oncology, University Hospital Marburg/Gießen, Marburg, Germany.

Amir Abdollahi (A)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Maximilian Knoll (M)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

David Kaul (D)

Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany. david.kaul@charite.de.
Charité - Universitätsmedizin Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany. david.kaul@charite.de.

Classifications MeSH